BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schein CH. Repurposing approved drugs on the pathway to novel therapies. Med Res Rev 2020;40:586-605. [PMID: 31432544 DOI: 10.1002/med.21627] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Andersson JA, Peniche AG, Galindo CL, Boonma P, Sha J, Luna RA, Savidge TC, Chopra AK, Dann SM. New Host-Directed Therapeutics for the Treatment of Clostridioides difficile Infection. mBio 2020;11:e00053-20. [PMID: 32156806 DOI: 10.1128/mBio.00053-20] [Reference Citation Analysis]
2 Li G, Zhang P, Sun W, Ren C, Wang L. Bridging-BPs: a novel approach to predict potential drug-target interactions based on a bridging heterogeneous graph and BPs2vec. Brief Bioinform 2022:bbab557. [PMID: 35037024 DOI: 10.1093/bib/bbab557] [Reference Citation Analysis]
3 Kamo M, Ito M, Toma T, Gotoh H, Shimozono R, Nakagawa R, Koga R, Monde K, Tateishi H, Misumi S, Otsuka M, Fujita M. Discovery of anti-cell migration activity of an anti-HIV heterocyclic compound by identification of its binding protein hnRNP M. Bioorg Chem 2021;107:104627. [PMID: 33476868 DOI: 10.1016/j.bioorg.2021.104627] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Schein CH. Repurposing approved drugs for cancer therapy. Br Med Bull 2021;137:13-27. [PMID: 33517358 DOI: 10.1093/bmb/ldaa045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Schein CH. Repurposing approved drugs on the pathway to novel therapies. Med Res Rev 2020;40:586-605. [PMID: 31432544 DOI: 10.1002/med.21627] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
6 Zhen Y, Yuan Z, Zhang J, Chen Y, Fu Y, Liu Y, Fu L, Zhang L, Zhou XL. Flubendazole induces mitochondrial dysfunction and DRP1-mediated mitophagy by targeting EVA1A in breast cancer. Cell Death Dis 2022;13:375. [PMID: 35440104 DOI: 10.1038/s41419-022-04823-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wang X, Li B, Kim YJ, Wang YC, Li Z, Yu J, Zeng S, Ma X, Choi IY, Di Biase S, Smith DJ, Zhou Y, Li YR, Ma F, Huang J, Clarke N, To A, Gong L, Pham AT, Moon H, Pellegrini M, Yang L. Targeting monoamine oxidase A for T cell-based cancer immunotherapy. Sci Immunol 2021;6:eabh2383. [PMID: 33990379 DOI: 10.1126/sciimmunol.abh2383] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Foulkes DM, McLean K, Haneef AS, Fernig DG, Winstanley C, Berry N, Kaye SB. Pseudomonas aeruginosa Toxin ExoU as a Therapeutic Target in the Treatment of Bacterial Infections. Microorganisms 2019;7:E707. [PMID: 31888268 DOI: 10.3390/microorganisms7120707] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
9 Thyagarajan A, Forino AS, Konger RL, Sahu RP. Dietary Polyphenols in Cancer Chemoprevention: Implications in Pancreatic Cancer. Antioxidants (Basel) 2020;9:E651. [PMID: 32717779 DOI: 10.3390/antiox9080651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Wall G, Lopez-Ribot JL. Screening Repurposing Libraries for Identification of Drugs with Novel Antifungal Activity. Antimicrob Agents Chemother 2020;64:e00924-20. [PMID: 32660991 DOI: 10.1128/AAC.00924-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Zheng W, D'Aiuto L, Demers MJ, Muralidaran V, Wood JA, Wesesky M, Chattopadhyay A, Nimgaonkar VL. Insights into bioinformatic approaches for repurposing compounds as anti-viral drugs. Antivir Chem Chemother 2021;29:20402066211036822. [PMID: 34463534 DOI: 10.1177/20402066211036822] [Reference Citation Analysis]
12 Benchoua A, Lasbareilles M, Tournois J. Contribution of Human Pluripotent Stem Cell-Based Models to Drug Discovery for Neurological Disorders. Cells 2021;10:3290. [PMID: 34943799 DOI: 10.3390/cells10123290] [Reference Citation Analysis]
13 Amahong K, Yan M, Li J, Yang N, Liu H, Bi X, Vuitton DA, Lin R, Lü G. EgGLUT1 Is Crucial for the Viability of Echinococcus granulosus sensu stricto Metacestode: A New Therapeutic Target? Front Cell Infect Microbiol 2021;11:747739. [PMID: 34858873 DOI: 10.3389/fcimb.2021.747739] [Reference Citation Analysis]
14 Harrell CR, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Mesenchymal Stem Cell-Derived Exosomes and Other Extracellular Vesicles as New Remedies in the Therapy of Inflammatory Diseases. Cells. 2019;8. [PMID: 31835680 DOI: 10.3390/cells8121605] [Cited by in Crossref: 105] [Cited by in F6Publishing: 113] [Article Influence: 35.0] [Reference Citation Analysis]
15 Wang YC, Wang X, Yu J, Ma F, Li Z, Zhou Y, Zeng S, Ma X, Li YR, Neal A, Huang J, To A, Clarke N, Memarzadeh S, Pellegrini M, Yang L. Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy. Nat Commun 2021;12:3530. [PMID: 34112755 DOI: 10.1038/s41467-021-23164-2] [Reference Citation Analysis]
16 Heydarzadeh S, Kia SK, Zarkesh M, Pakizehkar S, Hosseinzadeh S, Hedayati M, Hrelia S. The Cross-Talk between Polyphenols and the Target Enzymes Related to Oxidative Stress-Induced Thyroid Cancer. Oxidative Medicine and Cellular Longevity 2022;2022:1-20. [DOI: 10.1155/2022/2724324] [Reference Citation Analysis]
17 Joharatnam-Hogan N, Alexandre L, Yarmolinsky J, Lake B, Capps N, Martin RM, Ring A, Cafferty F, Langley RE. Statins as Potential Chemoprevention or Therapeutic Agents in Cancer: a Model for Evaluating Repurposed Drugs. Curr Oncol Rep 2021;23:29. [PMID: 33582975 DOI: 10.1007/s11912-021-01023-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Kouhpayeh H. A Systematic Review of Treatment Strategies Including Future Novel Therapies in Crimean-Congo Hemorrhagic Fever. Int J Infect 2021;8. [DOI: 10.5812/iji.113427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Schäkel L, Mirza S, Pietsch M, Lee SY, Keuler T, Sylvester K, Pelletier J, Sévigny J, Pillaiyar T, Namasivayam V, Gütschow M, Müller CE. 2-Substituted thienotetrahydropyridine derivatives: Allosteric ectonucleotidase inhibitors. Arch Pharm (Weinheim) 2021;:e2100300. [PMID: 34697820 DOI: 10.1002/ardp.202100300] [Reference Citation Analysis]
20 Ezquerra-Aznárez JM, Almeida da Silva PE, Aínsa JA. Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs. Microorganisms 2021;9:2335. [PMID: 34835459 DOI: 10.3390/microorganisms9112335] [Reference Citation Analysis]
21 Dubey KK, Indu, Sharma M. Reprogramming of antibiotics to combat antimicrobial resistance. Arch Pharm 2020;353:2000168. [DOI: 10.1002/ardp.202000168] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Liu Y, She P, Xu L, Chen L, Li Y, Liu S, Li Z, Hussain Z, Wu Y. Antimicrobial, Antibiofilm, and Anti-persister Activities of Penfluridol Against Staphylococcus aureus. Front Microbiol 2021;12:727692. [PMID: 34489917 DOI: 10.3389/fmicb.2021.727692] [Reference Citation Analysis]
23 Silva JRA, Kruger HG, Molfetta FA. Drug repurposing and computational modeling for discovery of inhibitors of the main protease (Mpro) of SARS-CoV-2. RSC Adv 2021;11:23450-8. [PMID: 35479789 DOI: 10.1039/d1ra03956c] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
24 Berns A, Ringborg U, Celis JE, Heitor M, Aaronson NK, Abou-Zeid N, Adami HO, Apostolidis K, Baumann M, Bardelli A, Bernards R, Brandberg Y, Caldas C, Calvo F, Dive C, Eggert A, Eggermont A, Espina C, Falkenburg F, Foucaud J, Hanahan D, Helbig U, Jönsson B, Kalager M, Karjalainen S, Kásler M, Kearns P, Kärre K, Lacombe D, de Lorenzo F, Meunier F, Nettekoven G, Oberst S, Nagy P, Philip T, Price R, Schüz J, Solary E, Strang P, Tabernero J, Voest E. Towards a cancer mission in Horizon Europe: recommendations. Mol Oncol 2020;14:1589-615. [PMID: 32749074 DOI: 10.1002/1878-0261.12763] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
25 Pillaiyar T, Meenakshisundaram S, Manickam M, Sankaranarayanan M. A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery. Eur J Med Chem 2020;195:112275. [PMID: 32283298 DOI: 10.1016/j.ejmech.2020.112275] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
26 Dos Santos AN, de L Nascimento TR, Gondim BLC, Velo MMAC, de A Rêgo RI, do C Neto JR, Machado JR, da Silva MV, de Araújo HWC, Fonseca MG, Castellano LRC. Catechins as Model Bioactive Compounds for Biomedical Applications. Curr Pharm Des 2020;26:4032-47. [PMID: 32493187 DOI: 10.2174/1381612826666200603124418] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
27 Madugula SS, John L, Nagamani S, Gaur AS, Poroikov VV, Sastry GN. Molecular descriptor analysis of approved drugs using unsupervised learning for drug repurposing. Comput Biol Med 2021;138:104856. [PMID: 34555571 DOI: 10.1016/j.compbiomed.2021.104856] [Reference Citation Analysis]
28 Della Pelle G, Kostevšek N. Nucleic Acid Delivery with Red-Blood-Cell-Based Carriers. Int J Mol Sci 2021;22:5264. [PMID: 34067699 DOI: 10.3390/ijms22105264] [Reference Citation Analysis]